Skip to main content
. 2020 Dec 25;13(1):38. doi: 10.3390/cancers13010038

Figure 1.

Figure 1

Structural domains of our main FMC63 anti-CD19 CARs. The structural design of the (a) 8-8-41BB CARs, (b) 28-28-28 CARs, (c) 28-28-41BB CARs and (d) IgG4-28-41BB CARs reviewed here. The individual scFv, hinge, transmembrane domain, costimulatory domain and signalling tails are labelled. Horizontal lines between hinge domains indicate disulfide bonds.